Cat. No. Name Size Price Add Cart
KI0275MP-4702 mg$211.2
MP-4705 mg$369.6
MP-47010 mg$651.2
MP-47050 mg$1531.2

Chemical Characteristic

Product NameMP-470
SynonymsAmuvatinib
CAS No.850879-09-03
Molecular Weight 447.51
FormulaC23H21N5O3S
Chemical NameN-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide
SmilesN1(CCN(CC1)c1c2c(ncn1)c1c(o2)cccc1)C(=S)NCc1cc2OCOc2cc1
Chemical Structure

Biological activities

MP-470 is a novel orally bioavailable mutitargeting tyrosine kinase inhibitor with activity against mutant c-KIT, PDGFRa and FLT3. MP-470 synergizes with docetaxel and is cytotoxic to Gastrointestinal stromal tumors cells (GIST) with IC50 values of 0.3-0.5 µM. [1] Meanwhile, MP-470 alone can inhibit eight glioblastoma cells (GBM) with IC50 values ranging from 1 µM to 10 µM (median 5 µM). MP-470 reduces c-Met phosphorylation and enhances radiation-induced cell kill by 0.4 logs in SF767 cells. MP-470 is shown to inhibit dsDNA break repair and increase apoptosis, MP-470 also influences various survival and DNA repair related proteins such as pAKT, RAD51 and GSK3β. The addition of MP-470 to radiation results in a tumor-growth-delay enhancement ratio of 2.9 over radiation alone and extends survival time.[2] At the same time, MP-470 of 0.66 µM can kill 50% H1299 clonogenic cells, 1-2.5 µM can decrease RAD51 expression with small changes in cell cycle progression in a dose-dependent manner.[3] Besides that, MP-470 inhibits cell proliferation, induces cell growth arrest and promotes apoptosis in prostate LNCaP and PC-3 cells with IC50s of ~4 µM and 8 mµ. Furthermore, MP-470-Erlotinib combination produces 30-65% dose-dependent tumor growth inhibition in a LNCap mouse xenograft model. [4]

Protocols

MP-470 is dissolved in DMSO. [2]

References

[1] Mahadevan D, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007, 26: 3909-3919.
[2] James WW, et al. The c-Met receptor tyrosine kinase inhibitor MP-470 radiosensitizes glioblastoma cells. Radiat Oncol. 2009, 4: 69.
[3] Helen Z, et al. The receptor tyrosine kinase inhibitor amuvatinib (MP-470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. 2011, 101(1): 59-65.
[4] Qi W, e t al. MP470, a novel receptor tyrosine kinase inhibitor,in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer. 2009, 9:142.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.